Understanding the factors affecting influenza and pneumococcal vaccination in cardiac patients
Read Online
Share

Understanding the factors affecting influenza and pneumococcal vaccination in cardiac patients

  • 58 Want to read
  • ·
  • 3 Currently reading

Published .
Written in English


Book details:

Edition Notes

Toronto, Uiversity Health Network

The Physical Object
Pagination44 leaves
Number of Pages44
ID Numbers
Open LibraryOL21870435M

Download Understanding the factors affecting influenza and pneumococcal vaccination in cardiac patients

PDF EPUB FB2 MOBI RTF

  The flu shot has a long, established safety record in people with heart disease. The live attenuated influenza vaccine (LAIV) or the nasal spray vaccine, is an option for people who are not pregnant and who are 2 through 49 years of age. But, people with some chronic medical conditions (such as heart disease) should generally not receive LAIV. Significant studies evaluating the effect of influenza and pneumococcal vaccination on the course of cardiovascular diseases published in recent years. Abbreviations: CHD - coronary heart disease, HF - heart failure, LVEF - left ventricle ejection fraction, ACS - acute coronary by: 6.   OBJECTIVE: This cross-sectional survey assessed factors associated with influenza and pneumococcal vaccination behaviors among high-risk patients exposed to highly organized vaccination programs. INTERVENTIONS: Self-administered questionnaires were mailed to patients randomly selected from the outpatient roster of the medical by: To address some of these issues, communication strategies around the safety and effectiveness of the inactivated influenza and acellular pertussis vaccines in pregnancy have targeted pregnant women and HCW in some settings,.However, a vaccine hesitancy literature review conducted by The Vaccine Confidence Project in found only 42 out of articles focusing on vaccination during Cited by:

The Role of Vaccination. All-cause Mortality Influenza vaccination has been associated with a 50% reduction in all-cause mortality in healthy elderly persons6. In a Swedish sample of , individuals >65 years of age, a combined influenza/pneumococcal vaccination resulted in a 57% decrease in all-cause mortality7. In a subset of patients with linked Medicare claims, vaccinated patients had similar rates of 1-year all-cause mortality (adjusted hazard ratio, [95% CI, ] for influenza vaccination; adjusted hazard ratio, [95% CI, ] for pneumococcal vaccination) . Successful vaccination of the elderly against important infectious pathogens which cause high morbidity and mortality represents a growing public health priority. Building upon the theme of aging and immunosenescence, we review mechanisms of human immunosenescence and the immune response to currently-licensed by: [36][37][38][39][40][41][42][43] The lower uptake of zoster vaccine among care home residents adds to a number of studies investigating uptake of other vaccines such as influenza and pneumococcal.

  This study found many participants knew guidelines existed ( %), but had low awareness of the benefits of vaccination in patients with asthma (40 %), as well as heart disease and diabetes ( %). A study by Shoefer et al. showed % and % of asthma patients receiving influenza and pneumococcal vaccines, respectively. Foreword. With the publication of the Immunisation Handbook (the Handbook), it is once again appropriate to extend the Ministry of Health’s thanks to everyone involved in supporting, promoting or delivering immunisations to the people of New Handbook has been designed as a comprehensive source of information on immunisation, to support you in the work you do. A systematic review of the determinants of influenza and pneumococcal vaccination in the elderly, which included 14 studies from around the world, not including Canada, found the strongest. A recent SRMA of six randomized controlled trials of patients confirmed that the influenza vaccination was associated with a lower rate of CC (RR: , 95% CI: –). 90 However, the mean follow‐up was 8 months, with a vanishing effect after 9–12 months of vaccination. Thus, we could conclude that influenza vaccination may Cited by: